Search

SNIPR Biome ApS - Treating and Preventing Microbial Infections

USPTO published patent application US20260098259A1 assigned to SNIPR Biome ApS, covering methods for treating microbial infections including acute conditions such as sepsis, septicemia, SIRS, and septic shock. The application also discloses methods for controlling microbiologically influenced corrosion (MIC) and biofouling in industrial or domestic systems.

Mammalian Cell SHMT2 Reduction for Protein Production

USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated SHMT2 expression and methods for using such cells in recombinant protein production. The application names Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, and Trissa Borgschulte as inventors. Filing date was September 29, 2023, under application number 19112697.

IL-8 Signal Inhibitor Composition for Prophylaxis or Treatment of IL-8 Related Diseases

USPTO published patent application US20260098086A1 on April 9, 2026, covering compositions for prophylaxis or treatment of IL-8 related diseases using IL-8 signal inhibitors and anti-IL-8 antibodies. The application was filed December 5, 2025, by inventors Ayako KAKIUCHI, Atsuhiko Kato, Shuji Hayashi, Izumi Yanagisawa, Ryo Konno, Sachiho Netsu, and Tadashi Sankai. The published application contains CPC classifications related to antibodies and therapeutic compositions.

Dosages of Emactuzumab for TGCT Treatment, SYNOX Therapeutics

The USPTO published patent application US20260098087A1 by SYNOX Therapeutics UK Limited covering dosage regimens of emactuzumab, an anti-CSF-1R antibody, for treating tenosynovial giant cell tumour (TGCT). The application, filed October 20, 2025, describes treatment regimes and methods using the colony stimulating factor-1 receptor-binding antibody. The application is now publicly available as part of the standard patent examination process.

Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof

The USPTO has published patent application US20260097127A1 for multimeric T-cell modulatory polypeptides comprising immunomodulatory polypeptides and epitope-presenting Wilms tumor peptides. The application, filed October 6, 2025, names Saso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel III, and John F. Ross as inventors. The published application covers methods for modulating T-cell activity and immune responses using the disclosed polypeptides.

Protein Purification Using Chemically Activated Carbon at 0.1-15 wt%

USPTO published patent application US20260098056A1 for a method of purifying proteins from fermentation-derived solutions using chemically activated carbon. The method involves contacting the solution with 0.1-15 wt% activated carbon at pH 4-12 and temperature 2-60°C. Inventors: Sebastian Schoof, Thomas Kaeding, Gabriele Iffland. Application filed October 6, 2025.

AMD Treatment with VEGF Antagonist Dosing at 8 or 12 Weeks

USPTO published patent application US20260098085A1 titled 'Methods for Treating Age-Related Macular Degeneration.' The application covers methods for reducing treatment burden for patients with intraocular neovascular disorders by administering VEGF antagonists on 8-week and/or 12-week dosing schedules. Inventors include Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, and Andreas Weichselberger. The application was filed on June 25, 2025.

siRNA Molecules Targeting ATXN3 Gene for Spinocerebellar Ataxia Treatment

The USPTO published patent application US20260098265A1 disclosing single- or double-stranded siRNA molecules targeting the ataxin-3 (ATXN3) gene for treatment of spinocerebellar ataxias, including spinocerebellar ataxia type 3. The application includes branched siRNA designs (di-branched, tri-branched, tetra-branched) with nucleoside modifications, 5' phosphorus stabilizing moieties, and methods for CNS delivery. The application was filed on September 28, 2023.

Genentech Modified CHO Cells for Therapeutic Protein Production

USPTO published patent application US20260098254A1 by Genentech, Inc. covering modified CHO cells for therapeutic protein production. The application claims methods, cells, and compositions where mammalian cells have reduced or eliminated activity of host cell proteins including lipases, esterases, and hydrolases. Application No. 19408114 was filed December 3, 2025.

Modified siRNA Targeting C9orf72 Gene for Neurological Disorder Treatment

USPTO published patent application US20260098264A1 for modified single- or double-stranded siRNA molecules targeting the C9orf72 gene for treatment of neurological disorders including amyotrophic lateral sclerosis and frontotemporal dementia. The application covers branched siRNA structures with nucleoside modifications, phosphorus stabilizing moieties, and methods for CNS delivery.